Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial - Concepedia

Concepedia

Publication | Open Access

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

DOI Full Paper Access

70

Citations

20

References

2022

Year

Jiong Wu, Zefei Jiang, Zhenzhen Liu, Benlong Yang, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu,

References

	Year	Citations

Page 1